SG10201811475YA - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) - Google Patents

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Info

Publication number
SG10201811475YA
SG10201811475YA SG10201811475YA SG10201811475YA SG10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA SG 10201811475Y A SG10201811475Y A SG 10201811475YA
Authority
SG
Singapore
Prior art keywords
methods
antibodies
receptor
stimulating factor
colony stimulating
Prior art date
Application number
SG10201811475YA
Other languages
English (en)
Inventor
Julie Hambleton
Emma Masteller
James Zanghi
Robert Sikorski
Hong Xiang
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of SG10201811475YA publication Critical patent/SG10201811475YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
SG10201811475YA 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) SG10201811475YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462015710P 2014-06-23 2014-06-23

Publications (1)

Publication Number Publication Date
SG10201811475YA true SG10201811475YA (en) 2019-02-27

Family

ID=53674259

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811475YA SG10201811475YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201610672YA SG11201610672YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610672YA SG11201610672YA (en) 2014-06-23 2015-06-18 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)

Country Status (13)

Country Link
US (2) US10975153B2 (OSRAM)
EP (1) EP3157957A1 (OSRAM)
JP (2) JP6964410B2 (OSRAM)
KR (2) KR20170016501A (OSRAM)
CN (2) CN106795222A (OSRAM)
AU (1) AU2015280362B2 (OSRAM)
BR (1) BR112016029460A2 (OSRAM)
CA (1) CA2951156A1 (OSRAM)
EA (1) EA037561B1 (OSRAM)
IL (1) IL249393B (OSRAM)
MX (1) MX391735B (OSRAM)
SG (2) SG10201811475YA (OSRAM)
WO (1) WO2015200089A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN109053887B (zh) * 2018-07-18 2019-07-23 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及用途
CN108948199B (zh) * 2018-07-18 2019-06-21 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其用途
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
JP2023553538A (ja) * 2020-12-14 2023-12-21 エーマックス バイオ， インコーポレイテッド 抗ｃｓｆ１および抗ｃｓｆ１ｒ抗体の高濃度製剤

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0955365A3 (en) 1992-06-09 2000-12-20 Chiron Corporation Crystallization of M-CSF
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH10218791A (ja) 1997-01-31 1998-08-18 Toagosei Co Ltd 慢性関節リウマチ治療薬
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
DE60024436T2 (de) 1999-05-07 2006-08-17 Genentech, Inc., South San Francisco Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
DE50002293D1 (de) 1999-10-28 2003-06-26 Hofbauer Reinhold Verwendung von csf-1-inhibitoren
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
JP4727992B2 (ja) 2002-11-15 2011-07-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌転移および癌転移に伴なう骨量減少を予防および処置するための方法
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
JP2007524671A (ja) 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
WO2005113596A2 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP2287310B1 (en) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Compositions and methods using MGD-CSF in disease treatment
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
DE602006011574D1 (de) 2005-01-27 2010-02-25 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009515521A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
KR101358600B1 (ko) 2005-12-22 2014-02-06 조마 테크놀로지 리미티드 가용성 인간 ｍ-ｃｓｆ 수용체 및 이의 용도
RU2470665C2 (ru) 2006-01-05 2012-12-27 Новартис Аг Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
AU2007248493B2 (en) 2006-05-04 2010-09-30 The Rockefeller University HCV coreceptor and methods of use thereof
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
ATE494306T1 (de) 2007-02-14 2011-01-15 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
PT2188313T (pt) 2007-08-21 2017-12-12 Amgen Inc Proteínas de ligação ao antigénio c-fms humano
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US20090148883A1 (en) 2007-10-31 2009-06-11 Manthey Carl L Biomarker for assessing response to fms treatment
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2262836B1 (en) 2008-03-14 2016-03-09 Transgene SA Antibody against the csf-1 r
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
KR101434070B1 (ko) 2009-12-10 2014-08-25 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ 세포외 도메인 4에 우선적으로 결합하는 항체 및 그의 용도
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3357510B1 (en) * 2010-05-04 2020-08-05 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
EP2768861A1 (en) 2011-10-21 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
SG11201401639QA (en) 2011-10-21 2014-05-29 Transgene Sa Modulation of macrophage activation
CA2871445C (en) * 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN107567336B (zh) * 2014-10-29 2021-12-31 戊瑞治疗有限公司 癌症的联合治疗

Also Published As

Publication number Publication date
EP3157957A1 (en) 2017-04-26
KR20170016501A (ko) 2017-02-13
CN106795222A (zh) 2017-05-31
AU2015280362B2 (en) 2021-03-04
US10975153B2 (en) 2021-04-13
US20170152320A1 (en) 2017-06-01
SG11201610672YA (en) 2017-01-27
EA201692482A1 (ru) 2017-05-31
MX2016016664A (es) 2017-03-20
IL249393B (en) 2022-02-01
CA2951156A1 (en) 2015-12-30
CN113350501A (zh) 2021-09-07
IL249393A0 (en) 2017-02-28
MX391735B (es) 2025-03-21
JP2017520562A (ja) 2017-07-27
AU2015280362A1 (en) 2016-12-22
US20210317219A1 (en) 2021-10-14
JP2020169179A (ja) 2020-10-15
KR20230086809A (ko) 2023-06-15
WO2015200089A1 (en) 2015-12-30
JP6964410B2 (ja) 2021-11-10
BR112016029460A2 (pt) 2017-10-24
EA037561B1 (ru) 2021-04-14

Similar Documents

Publication Publication Date Title
SG10201906328RA (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ZA202307128B (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
MX2017008218A (es) Anticuerpos anti-csf1r para tratar pvns.
HK1208233A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
PH12017500915A1 (en) Cd47 antibodies, methods, and uses
PH12019502283A1 (en) Anti-lag3 antibodies
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014501758A1 (en) Cd47 antibodies and methods of use thereof
PH12021552158A1 (en) Antibodies to icos
PH12016501908A1 (en) Bispecific antibodies that bind to cd38 and cd3
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
MX2016012371A (es) Anticuerpos multiespecificos.
PH12016501366A1 (en) Novel anti-baff antibodies
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
SG10201811475YA (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
EA201691112A1 (ru) Образование антител ex vivo